
Opinion|Videos|July 29, 2024
Out of Pocket Costs Associated with Biosimilar Use
The panel discusses out of pocket costs and the impact of the 340b program for various patient types.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sevabertinib for Nonsquamous NSCLC
2
Medicaid Work Requirements Mirror Programs in Georgia, Arkansas: Ciara Zachary, PhD, MPH
3
Herbal Use Linked to Lower Autoantibodies in Dermatomyositis
4
How Effective and Safe Are GLP-1s for Weight Loss?
5













































